Frontline Daratumumab Regimen Approved in EU for Transplant-Eligible Myeloma
The European Commission has granted marketing authorization for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Source: OncLive